Mr. Aselage has been a member of the board of directors of Travere Therapeutics, Inc. since 2012. During his tenure as CEO of Travere from 2014 to January 2019, Mr. Aselage drew upon more than 30 years of biopharmaceutical experience to lead the transformation of the company. Following his appointment, Mr. Aselage solidified the company’s leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders. Prior to his appointment, Mr. Aselage was executive vice president and chief business officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the board of directors for Acer Therapeutics and BioCryst. Mr. Aselage received his B.S. in biology from the University of Notre Dame, and currently serves on the advisory council for the Department of Science at Notre Dame.
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.